The Evolution of WHO Meningioma Grading Criteria

The clinical management of primary intracranial tumors requires accurate histopathological grading to estimate recurrence risk. In 2016, the World Health Organization designated microscopic brain invasion as a standalone diagnostic criterion for grade 2 atypical meningiomas. Consequently, even histologically benign tumors receive an atypical designation whenever neoplastic cells breach the pial surface. This significant diagnostic change sparked debate regarding grade 2 meningioma progression in tumors lacking other classic cellular hallmarks of atypia. Historically, pathologists diagnosed atypia based on elevated mitotic activity, spontaneous necrosis, or sheet-like growth patterns. Introducing parenchymal invasion as an independent criterion expanded the grade 2 patient cohort substantially. However, mechanical compressive forces from large tumors may disrupt the brain-tumor interface without true biological invasiveness. As a result, clinicians question whether solitary invasion predicts recurrence as aggressively as traditional histological features. Clarifying this prognostic distinction is essential for optimizing surveillance regimens, avoiding unwarranted adjuvant radiation, and reducing patient distress.

Investigating Brain Invasion Otherwise Benign Lesions

To evaluate this question, investigators conducted a retrospective cohort study examining resected atypical meningiomas over two decades. Specifically, researchers analyzed 131 patients treated between 2003 and 2023, meticulously re-grading all tumors under current diagnostic criteria. The study categorized patients into two distinct analytical groups for comparison. The first cohort comprised brain invasion otherwise benign lesions, termed the BIOB group. These tumors showed cortical breach but lacked high mitotic counts or other atypical architectural features. In contrast, the second cohort included tumors meeting conventional atypical criteria, such as elevated mitoses or necrosis. By evaluating time-to-recurrence between these groups, investigators assessed whether invasion alone drives aggressive clinical behavior independently of tumor volume. Furthermore, the analysis controlled for surgical resection margins, patient demographics, and postoperative radiotherapy. Baseline demographic features and tumor volumes remained well balanced across both study cohorts. Consequently, this study design provided a robust framework to isolate the prognostic influence of solitary parenchymal invasion.

Clinical Findings on Grade 2 Meningioma Progression

The investigation revealed striking differences in clinical outcomes between the two atypical tumor groups. Over a mean radiographic follow-up of 74 months, recurrence occurred in 31% of all study patients. However, meningiomas in the BIOB group exhibited a progression rate of only 17.8%. In contrast, tumors displaying other traditional atypical features recurred in 37.2% of cases during follow-up. Moreover, univariate Cox proportional hazards regression showed that BIOB status conferred a significantly reduced recurrence risk. Grade 2 meningioma progression correlated strongly with traditional atypical cellular features rather than isolated brain invasion. Additionally, the extent of surgical resection exerted a massive impact on progression-free survival. Patients undergoing gross total resection demonstrated superior disease control compared to those receiving subtotal resections. Multivariate modeling confirmed that classic histological atypia independently predicts early disease recurrence. Therefore, these clinical findings indicate that isolated brain invasion does not confer the same malignant risk as multi-featured atypical lesions.

Mechanisms Driving Differences in Recurrence Risk

Understanding why isolated invasion does not accelerate recurrence requires examining meningioma biomechanics and molecular biology. Traditionally, pathologists consider parenchymal breach a hallmark of cellular invasiveness and aggressive biological behavior. However, meningiomas expand within a rigid intracranial cavity where expanding tumor mass generates substantial hydrostatic force. Consequently, mechanical friction against the arachnoid membrane may cause focal microscopic tearing of the glia limitans. Benign tumor cells can then extend into superficial parenchyma without acquiring aggressive genetic alterations. In contrast, biologically aggressive atypical meningiomas harbor specific molecular alterations, including TERT promoter mutations or CDKN2A deletions. Furthermore, tumors with high mitotic rates undergo accelerated cell division and exhibit resistance to apoptosis. These intrinsic drivers promote rapid tumor proliferation and prompt post-surgical recurrence. Because BIOB lesions usually lack these high-risk genetic alterations, their growth kinetics remain indolent. Hence, microscopic invasion in an otherwise benign tumor often reflects mechanical remodeling rather than aggressive underlying biology.

Surgical Extent and Postoperative Radiotherapy Considerations

The study reinforces the foundational role of complete surgical resection in achieving long-term local tumor control. Across the patient cohort, gross total resection substantially decreased the hazard of subsequent disease progression. Neurosurgeons often encounter technical challenges when detaching invasive tumors from adherent, eloquent brain parenchyma. Nevertheless, achieving complete resection remains the single most impactful surgical goal for preventing recurrence. In addition, the study evaluated the role of postoperative adjuvant radiotherapy. Only 14% of patients received adjuvant radiation, reflecting selective institutional practice patterns. International guidelines frequently recommend routine adjuvant radiotherapy for atypical meningiomas to reduce recurrence rates. However, delivering routine radiation to patients with BIOB tumors could cause unwarranted overtreatment, especially following gross total resection. Radiotherapy carries tangible risks of neurocognitive decline, pituitary dysfunction, and radiation necrosis. Therefore, clinicians should carefully balance these treatment morbidities against the favorable natural history of solitary invasion. Tailoring radiation strategies prevents overtreatment while maintaining disease control.

Implications for Surveillance and Personalized Neuro-Oncology

These findings offer valuable insights for refining postoperative surveillance protocols and guiding patient communication. Currently, receiving a grade 2 atypical meningioma diagnosis generates considerable anxiety for patients and caregivers. When pathology reports identify brain invasion alone, neuro-oncology teams frequently schedule aggressive neuroimaging surveillance. However, these data suggest that patients with BIOB lesions experience outcomes resembling benign grade 1 tumors. Consequently, multidisciplinary neuro-oncology teams can reasonably consider less burdensome imaging intervals for gross-totally resected BIOB tumors. Furthermore, integrating comprehensive molecular testing, including DNA methylation profiling and cytogenetic analysis, will enhance standard histopathological grading. Molecular diagnostics can accurately separate indolent invasive lesions from biologically aggressive tumors requiring immediate intervention. By combining precise histological evaluation with advanced molecular biomarkers, clinicians can deliver personalized neuro-oncological care. Ultimately, recognizing the favorable prognosis of solitary brain invasion prevents therapeutic overtreatment while preserving patient quality of life.

Frequently Asked Questions

What defines a brain invasion otherwise benign meningioma?

A brain invasion otherwise benign meningioma displays microscopic parenchymal breach into adjacent brain tissue but lacks high-grade histological features. Specifically, these tumors do not exhibit elevated mitotic activity, spontaneous necrosis, or prominent architectural atypia. Consequently, their biological behavior remains relatively indolent compared to multi-featured atypical meningiomas.

Does brain invasion alone warrant routine adjuvant radiation therapy?

Routine adjuvant radiation may not be necessary for all patients exhibiting isolated brain invasion, particularly following gross total surgical resection. Because these lesions show lower progression rates than traditional atypical meningiomas, selective close surveillance offers an appropriate alternative. Clinicians must weigh individual recurrence risks against potential radiation-induced neurocognitive side effects.

How does surgical resection extent influence meningioma recurrence risk?

The extent of surgical resection represents a primary determinant of progression-free survival across all meningioma grades. Achieving gross total resection eliminates microscopic tumor nests along the dural base and brain interface. Consequently, complete resection dramatically lowers recurrence hazard ratios, whereas incomplete subtotal resections require vigilant radiographic monitoring and intervention.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Tos SM et al. Meningiomas classified as grade 2 due to brain invasion alone have better progression-free survival than other atypical meningiomas. J Neurooncol. 2026 Sep 11. doi: 10.1007/s11060-026-05783-1. PMID: 42726364.


2. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821-1834.


3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.